Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells

Although cancer patients exhibit a generalized immunosuppressive status, substantial evidence indicates that the inflammatory reaction at a tumor site can promote tumor growth and progression. Hepatocellular carcinoma (HCC) is usually derived from inflamed cirrhotic liver with extensive leukocyte infiltration. We recently found that proinflammatory T helper (Th)17 cells are accumulated in HCC tissue, where they promote disease progression by fostering angiogenesis. Here we show that interleukin (IL)‐17‐producing cells were enriched predominantly in peritumoral stroma of HCC tissues, and their levels were well correlated with monocyte/macrophage density in the same area. Most peritumoral CD68+ cells exhibited an activated phenotype. Accordingly, tumor‐activated monocytes were significantly superior to the suppressive tumor macrophages in inducing expansion of Th17 cells from circulating memory T cells in vitro with phenotypic features similar to those isolated from HCCs. Moreover, we found that tumor‐activated monocytes secreted a set of key proinflammatory cytokines that triggered proliferation of functional Th17 cells. Inhibition of monocytes/macrophages inflammation in liver markedly reduced the level of tumor‐infiltrating Th17 cells and tumor growth in vivo. Conclusion: The proinflammatory Th17 cells are generated and regulated by a fine‐tuned collaborative action between different types of immune cells in distinct HCC microenvironments, and allows the inflammatory response of activated monocytes to be rerouted in a tumor‐promoting direction. Selectively modulating the “context” of inflammatory response in tumors might provide a novel strategy for anticancer therapy. (HEPATOLOGY 2009.)

[1]  Jing Xu,et al.  Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 , 2009, The Journal of experimental medicine.

[2]  J. Xu,et al.  Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. , 2009, Journal of Hepatology.

[3]  J. Xu,et al.  High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. , 2009, Human pathology.

[4]  G. Galbraith IL-22 is required for Th17 cell–mediated pathology in a mouse model of psoriasis-like skin inflammation , 2009 .

[5]  Wan-Wan Lin,et al.  Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis , 2009, Nature.

[6]  J. Edwards,et al.  Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.

[7]  Wen-rong Gong,et al.  Cutting Edge: IFN-γ Enables APC to Promote Memory Th17 and Abate Th1 Cell Development1 , 2008, The Journal of Immunology.

[8]  S. Alzabin,et al.  Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells , 2008, The Journal of experimental medicine.

[9]  Warren Strober,et al.  Interactions among the transcription factors Runx1, RORγt and Foxp3 regulate the differentiation of interleukin 17–producing T cells , 2008, Nature Immunology.

[10]  K. Odunsi,et al.  Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer , 2008, Proceedings of the National Academy of Sciences.

[11]  J. Yun,et al.  Tumor-Educated Tolerogenic Dendritic Cells Induce CD3ε Down-Regulation and Apoptosis of T Cells through Oxygen-Dependent Pathways1 , 2008, The Journal of Immunology.

[12]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[13]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[14]  E. Barillot,et al.  A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses , 2008, Nature Immunology.

[15]  Chen Dong,et al.  TH17 cells in development: an updated view of their molecular identity and genetic programming , 2008, Nature Reviews Immunology.

[16]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[17]  M. McGeachy,et al.  Review Th17 Cell Differentiation: the Long and Winding Road , 2022 .

[18]  Wen-rong Gong,et al.  Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. , 2008, Journal of immunology.

[19]  D. Hommes,et al.  Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. , 2007, Immunity.

[20]  Graham M Lord,et al.  Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes , 2007, Proceedings of the National Academy of Sciences.

[21]  L. Cosmi,et al.  Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.

[22]  Jiasen Cheng,et al.  Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. , 2007, Blood.

[23]  Zheng Zhang,et al.  Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. , 2007, Gastroenterology.

[24]  A. Chang,et al.  Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment1 , 2007, The Journal of Immunology.

[25]  H. Moses,et al.  Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. , 2007, The Journal of clinical investigation.

[26]  R. Kastelein,et al.  Swords into plowshares: IL-23 repurposes tumor immune surveillance. , 2007, Trends in immunology.

[27]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[28]  Xin Wei Wang,et al.  Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. , 2006, Cancer cell.

[29]  Gefeng Zhu,et al.  B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma , 2006, The Journal of experimental medicine.

[30]  L. Coussens,et al.  Tumor stroma and regulation of cancer development. , 2006, Annual review of pathology.

[31]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[32]  R. Sun,et al.  Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of toll-like receptor 4 expression on macrophages. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Dufour,et al.  Angiogenesis and hepatocellular carcinoma. , 2004, Journal of hepatology.

[34]  N. Fusenig,et al.  Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.

[35]  A. Lindén,et al.  Interleukin-17 family members and inflammation. , 2004, Immunity.

[36]  J. Lötvall,et al.  Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. , 1999, Journal of immunology.

[37]  D. Laskin,et al.  Inhibition of macrophages with gadolinium chloride abrogates ozone-induced pulmonary injury and inflammatory mediator production. , 1995, American journal of respiratory cell and molecular biology.